Influence of smoking on manifestation and clinical outcome of acute ST elevation myocardial infarction in clinical practice: Results of the ACOS registry  by Meisenzahl, Christina et al.
JACC March 19,2003 
tmprovement in the invasive arm (mean difference +29.5, P=O.Ol, 18.5, P~0.04, respec- 
tively) and a trend in SAQ treatment satisfaction measure (mean difference +19.2, 
P=O.O7). All other measures were similar between the two arms. 
Conclusions: Patients undergoing invasive management after non-ST-segment eleva- 
tion AMI show improved functional status and quality of life. 
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administrated ix. 40 mg. before the first dose of 0.75 MU. of SK and 1 mg/kg every 12 
hours for 5-7 days. Heparin was infused 1000 i.u.ihour for 46-96 hoursThree noninva- 
sive reperfusion criteria were used: 1Rapid cessation of the chest pain. 2Rapid 
decreasing of the ST segment elevations by more than 50% from the initial value. 
3Rapid increasing of the CK and CK-MB with a peak within the first 12 hrs. 
Results. The chest pain-thrombolysis time was 143+/-71 min in the preASENOX sub- 
group, significantly shorter that the inASENOX subgroup (176+/-76 min., p=O.O16) and 
the StSK one (171+/-76 min., p=O.Oll). The ratios of the coronary repsrfusion were 
61.2%. 76.1% and 60.7%, respectively (preASENOX vs StSK p=O.O67; inASENOX vs 
StSK p=O.O44). The inhospital mortalities were: 3.12% (preASENOX); 5.9% (inASENOX) 
and 10.4% (StSK)(non-significant differences). Neither stroke nor other major haemorag- 
ical events were registered in the three subgroups. Simptomatic hypotansion was benign 
and appeared more frequent in the preASENOX (32%) and inASENOX (34%) subgroups 
as compared to the StSK one (20%). 
Conclusions: 1. The preASENOX and inASENOX regimens are safe and lead toward a 
significant higher ratios of coronary repetfusion as compared to the StSK one. 2. Our 
data sugest a very low mortality in patients treated with the preASENOX regimenfurther 
investigation are needed for certify this attractive regimen. 
1196-110 Left Ventricular Ejection Fraction, Enzyme Release, and 
Stent Implantation Are Independent Predictors of Late 
Clinical Outcome After Late Opening of Infarct-Related 
Occlusion 
Francois Schiela Lionel Thebault, Pradip &woke, Pierre Legalery. Marie-France 
Seronde, Nicolas Meneveau, Jean-Pierre L. Bassand, University Hospital Jean-Mintoz, 
Besancon, France 
Background. The potential benefit of n-opening occluded infarct-related arteries (IRA) by 
percutaneous coronary intervention (PCI) is still debated. We assessed the immediate 
and long term clinical outcome of patients submitted to systematic attempt at IRA re- 
opening in a setting of a sub acute (a72 hours and cl0 days) myocardial infarction (Ml). 
Methods and Results. 199 consecutive patients matching these criteria were submitted 
to PCI and followed up for one year. Three endpoints were defined: (1) = composite of 
death, new Q wave MI, pert-procedural creatine kinase (CK) release >3 times the upper 
limit of normal, stroke, major bleeding or need for urgent revascularfsation at 30 days; (2) 
= one year survival without stroke, new MI or unstable angina; and (3) = endpoint #2 plus 
need for target lesion ravascularization. Reopening of the IRA was successful 159/199 
(60%) patients, with stem implantation in 99 (50%). Endpoint #f occurred in 16 (6%) 
patients; endpoint #2 in 30 (15%) and endpoint (3) in 44 (22%). Two year event free 
probability was 0.75*0.05 and 0.72a0.04 for endpoints #2 and #3 respectively. Left ven- 
tricular ejection fraction (LVEF) (odds ratio = 0.66 [0.79;0.94], p=O.OOl per additional per- 
cent of LVEF) and CK release (1.01 [l.OO;l.Ol], p=O.O4 per additional unit of CK 
released) were independent predictors for endpoint #2, with LVEF being the only inde- 
pendent predictor of endpoint #3. Lack of stem implantation (odds ratio = 0.26 [0.05:0.5]. 
p=O.O4) and CK release (1.01 [l.OO;l.Ol], p=O.O3) were independent predictors of death. 
Conclusion: Clinical outcome of patients submitted to systematic attempts to m-open 
occluded IRA in the setting defined in this study is mostly influenced by post Ml LV func- 
tion. Peri-procedural enzyme leakage and lack of stem implantation negatively influence 
late clinical outcome. 
1196-111 Antibody Levels Against Chlamydia Pneumoniae and 
Outcome of Roxithromycin Therapy: Results From a 
Substudy of the Randomized Antibiotic Therapy in 
Acute Myocardial Infarction (ANTIBIO) Trial 
Ralf Zahn, Ulrich Burckhardt, Ulrich Hoffler, Birait Frillinq, Jochen Senges. ANTIBIO 
study group, Herzzentrum, Ludwigshafen, Germany 
Background: Treatment with a macrolide antibiotic for patients (pts) with coronary artery 
disease may be only effective in pts with elevated antibody titers against Chlamydia 
pneumoniae(Cp). Methods: We therefore analyzed a pm-specified subgroup of the dou- 
ble-blind placebo controlled ANTIBIO study. Pts with an acute myocardial infarction were 
treated with either 300mgIod roxithromycin or pfacebolod for 6 weeks. A follow-up was 
performed at 12 months. In 160 out of 672 pts blood samples were analyzed for antibody 
titers (IgG, IgA and IgM by an enzyme linked immunoassay) against QI The combined 
endpoint (CE) was death, myocardial infarction, stroke, unstable angina, coronary bal- 
loon angioplasty or bypass surgery during 12 months follow up. Results: Positive anti- 
body titers against Cp were prevalent in 61.9% of pts for IgG, 55.6% for IgA and 1.9% for 
IgM. A CE occurred in 36% of pts being IgG seropositive compared to 32% in seronega- 
tive pts, and m 41% IgA seropositive versus 26% IgA seronegative pts (all p=ns). 61 pts 
received roxithromycin and 79 placebo. In the roxithromycin group a CE occurred in 42% 
of pts seropositive for IgG against Cpcompared to 26% in pts being seronegative (p=ns). 
In the placebo group CE occurred in 23% IgG seropositive pts versus 47% in seronega- 
tive pts (p=O.O25). No significant treatment effects were also seen according to preva- 
lence of IgA titers or in higher elevated titers. Conclusion: Neither seropositivity for C+I 
nor the amount of titer elevation was associated with a higher clinical event rate during 
12 month of follow up after an acute myocardial infarction. Treatment with roxithromycin 
did not influence the rate of clinical events, independently of presence or amount of anti- 
body titer elevation against Cp. 
1196-112 Safety and Efficacy of an Accelerated Streptokinase 
Regimen in Combination With Enoxaparin in the 
Prehospital Management of the ST Acute Myocardial 
Infarction (ASENOX-2) Study 
Gabriel Tatu-Chitoiu, Mircea Oprisan. Ovidiu Cismara, Rodica Marinescu, Ad& 
Marinescu, Radu Turcu, Maria Dorobantu, Spitalul Clinic de Urgenta. Bucuresti, 
Romania, Serviciul de Ambulanta, Bucuresti, Romania 
Background. Recent data suggest a similar efficacy of the standard Streptokinase (SK) 
regimen (1.5 M.U.160 min.) either in combination with Heparin or Enoxaparin in ST acute 
myocardial infarctton (STAMI). 
Objective Safety and efficacy of an accelerated SK regimen (0.75 M.U.00 min. 
repeated after 50 min. if no signs of coronary repertusion were detected) in combination 
with Enoxaparin was evaluated in the prehospital (preASENOX regimen) and the inhos- 
pital (inASENOX regimen) phase of STAMI and compared to the standard SK plus Hep- 
arin (StSK regimen). 
Methods. A group of 266 consecutive patients, thrombolised within the first 6 hours after 
the onset of STAMI was divided in three subgroups according to the mentioned regi- 
mens: preASENOX (64 pts.); inASENOX (67 pts) and StSK (135 pts.). Enoxaparin was 
1196-113 Erythropoietin Augments Cardiomyocyte Survival and 
Left Ventricular Function After Hypoxia 
Cvrus J. Parsa, Akio Matsumoto, G. Brant Walton, Jonathan S. Stamler, Walter J. Koch, 
Duke University, Durham, NC 
Background: Erythropoietin (EPO) may have effects beyond hematopoiesis such as 
prevention of neuronal apoptosis secondary to ischemia. We evaluated EPO protection 
in myocardial ischemia. Methods: H9c2 myoblasts were used to test EPCYs protection 
against hypoxia-induced apoptosis. Cells were pretreated with EPO (0.4 or lOU/ml) for 
24 hours (hrs) and exposed to hypoxia (95%b-5%CO,) for 12 hrs followed by 12 hrs of 
m-oxygenation, or H9c2 cells were treated with EPO after hypoxia and before re-oxygen- 
ation. Also, 250mM hjOs for 22 hrs was used as an apoptotic stimulus. Cells were 
stained and analyzed for % apoptotic nuclei. To apply our findings in viva. we used a 
model of myocardial infarction (Ml) in rabbits. Animals were randomized to receive a sin- 
gle dose of EPO (5000 units/kg) or saline or sham (no Ml). On post-operative day (POD) 
3, hemodynamic measurements were obtained. Hematocrits were drawn on POD 0, 1, 3, 
and 4. Hearts were harvested on POD 4 and infarct size quantified. Results: The graph 
shows that under all conditions tested, EPO prevented apoptosis in myoblasts.ln dvo, 3 
days after MI, EPO treated rabbits exhibited improved LV function, including contractility 
(~~0.05) and exhibited smaller infarct size. Protective effects were seen without 
increased hematocrit. Conclusions: EPO augmented myocyte survival after ischemia in 
I-----_* 11-w _,,-_ll-_--__-” .._. __._“.~ 
vitroand in viva, reduced infarct size and reversed ventricular dysfunction post-MI. Thus, 
EPO may offer novel protection for myocardial ischemia. 
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869-1 Influence of Smoking on Manifestation and Clinical 
Outcome of Acute ST Elevation Myocardial Infarction in 
Clinical Practice: Results of the ACOS Registry 
Christina Meisenzahl Anselm K. Gin, Rudolf Schiele. Harm Wienbergen. Tobias Heer. 
Martin G. Gottwik, Heruentrum Ludwigshafen, Ludwigshafen, Germany, Klinikum 
Niimberg Sod. Ntimberg, Germany 
Background: Subgroup-analysis of large randomised trials with selected patients have 
shown a lower mortalitv after ST Elevation Mvocardial Infarction (STEMI) in smokers 
I  
compared to nonsmokers. Little data exist on the differences in outcome of STEMI 
between smokers and nonsmokers in clinical practice. 
Methods: Since June 2000 consecutive patients (pts) with acute coronary syndrome 
(STEMI, Non-ST Elevation Myocardial Infarction and unstable angina) have been 
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enrolled into the ACOS-Registry (Acute Coronary Syndrome, 154 hospitals) in Germany. 
We analysed the prospective data of STEMI-pts with special respect to the smoking sta- 
tus. 
Results: Out of 5122 consecutive pts with STEMI. 1852 (36%) were current smokers 
and 2753 (54%) had never smoked (nonsmokers). Smokers were at mean 15 years 
younger, more often male and had less often hypertension and diabetes as additional 
cardiovascular risk factors. Smokers did receive acute repelfusion therapy more often. 
The hospital mortality in nonsmokers was three times higher than in smokers. After cor- 
recting for differences in baseline characteristics and acute repedusion and adjunctive 
therapy rn a multivariate analysis smoking did not influence hospital mortality after 
STEMI (OR 0.80. 95% Cl 0.60-1.06). 
Conclusion: In smokers STEMI occurred 15 years earlier in age than in nonsmokers. In 
a multivariate analysis smoking did not influence the outcome of STEMI. 
Parameter 
Age (years) 
Male gender 
Prior MI 
Hypercholesteremia 
Hypertension 
Diabetes 
CK max (U/l) 
Acute Repedusion 
Thrombolysis 
Primary PCI 
Hospital Modality 
Smokers 
n=l852 
56 
81 .6 % 
6.4 % 
47.4 % 
45.0 % 
16.1 % 
625 
78.7 % 
26.7 % 
52.0 % 
4.7 % 
Nonsmokers 
n=2753 
71 
60.4 % 
12.8% 
40.2 % 
63.3 % 
30.5 % 
532 
64.6 % 
20.7 % 
44.1 % 
13.3 % 
p-value 
co.01 
<O.Ol 
<O.Ol 
<O.Ol 
<O.Ol 
co.01 
<O.Ol 
co.01 
<O.Ol 
<O.Ol 
co.01 
Et:45 a.m. 
869-2 Comparison of the Importance of Increasing Pathogen 
Burden, Elevated C-Reactive Protein, and the Presence 
of Antibodies to Heat Shock Protein 60 on Myocardial 
Infarction or Death 
Jianhui Zhq Stephen E. Epstein, Joseph B. Muhlestein, Javier F. Nreto, Amy 
Wasserman, Benjamin D. Home, David Rott, Jeffrey L. Anderson, Washington Hospital 
Center, Washington, DC, LDS Hospital, Salt Lake City, UT 
In addition to the importance of traditional risk factors, recent evidence suggests that 
infectious pathogens, C-reactive protein (CRP) and heat shock protein (HSP) play roles 
in the progression of atherosclerosis and can be used as outcome predictors. In the 
present study, we compared the relative importance of a) pathogen burden (seropositiv- 
iky to cytomegalovirus, hepatitis A virus, C. pneumoniae, H. pylori, herpes simplex virus 
type 1 and type 2) b) CRP levels, and c) anti-human HSPGO antibodies in predicting 
myocardial infarction (MI) or death. The patient cohorl consisted of 890 patients (77% 
men. mean age 65 years) with coronary artery disease (CAD) documented by coronary 
angiography (2 70% stenosis). The mean follow-up period was 3 years. By both univari- 
ate and Cox multivariate regression analyses, pathogen burden and elevated CRP levels 
were strong and independent predictors of incident Ml or death. The highest relative haz- 
ard was conveyed by pathogen burden (Table 1). In contrast, HSPGO antibodies were not 
significant determinants of MI or death. We conclude that in patients with documented 
CAD, both pathogen burden and elevated CRP levels are important independent predic- 
tors of MI or death, suggesting that infection and inflammation contribute to the disease 
processes leading lo acute coronary occlusion. Although HSPGO has been associated 
with angiographic evidence of the presence and extent of CAD, it’s role in the acute com- 
plications of CAD is still to be determined. 
Table 1. Comparison of Relative Hazard (95%CL) of Incident MI or Death 
Pathogen BurdenO-3 
4 
5 
6 
CRP Tadile 1 
2 
3 
HSPGO Ab (c) 
HSPGO Ab (-) 
Unadjusted Adjusted For CAD Risk Factors 
1 .o 
1.9 (0.6-4.4) 
3.2 (I .4-6.9) 
4.6 (2.1-9.9) 
1 .o 
1.9 (1.3-2.9) 
1 .Q (1.3-2.9) 
1.0 
1.2 (0.8-I .6) 
1 .o 
1.5 (0.6-3.5) 
2.6 (I .2-5.7) 
3.1 (1.4-6.8) 
1.0 
1.8 (I .2-2.6) 
1.7 (1.1-2.5) 
1.0 
1.2 (0.8-l .6) 
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869-3 Increased Concentrations of Bone Marrow-Derived 
Stem Cells in Peripheral Blood After Acute Myocardial 
Infarction 
Antonio Maria Leone, Sergio Rutella. Felicita Andreotti, Luca Pierelli, Mariaelena 
Lombardi, Giuseppe Leone, Filippo Crea, Universita Cattolica del Sacro Cuore, Rome, 
Italy 
Background: recent studies in expenmental models have shown that bone marrow- 
derived stem cells (BMSCs) can regenerate myocardial tissue after a myocardial infarc- 
tion. Moreover, the presence of cardiomyocytes of extracardiac origin has been reported 
in human transplanted heads. It is reasonable to assume, therefore, that EMSCs may be 
released into the peripheral blood after an acute myocardial infarctron (AMI). migrate 
towards the head, and there differentiate into cardiomyocytes to repas, at least in part, 
the damaged tissue. The awn of this study was to evaluate whether BMSC concentra- 
tions increase in peripheral blood after an AMI. Methods: BMSC concentratrons were 
measured by flow-Cytometry as CD34+ cellslmicroliter (mcl) rn the peripheral blood of 22 
patients with AMI after I, 3, 5 and 7 days from the event and in 11 healthy controls with- 
out cardiovascular risk factors of similar age, sex and race. Results In agreement with 
the literature, the median concentration of CD34+ cells in healthy controls was <l/mcl 
(0.47/mcl, interquartile range - IR - 0 to 0.94). In contrast, in the absence of clinical and 
laboratory findings of hemoconcentration, the median concentration of CD34+ cells in 
patients with AMI was significantly increased at 1, 3, 5 and 7 days from the event to 4.461 
mcl (IR 2.6 to 8.4, p=O.OOOS), 2.9l/mcl (IR 2.16 to 4.045, p=O.O014), 5.03imcl (IR 2.36 to 
7.9, p=O.O013). and 7.925 (IR 5.26 to 12.68, p=O.O075), respectively (Figure). Conclu- 
sions: In patients with AMI there is an increase in peripheral bone marrow-derived stem 
cell concentrations. These results support the hypothesis that these cells may migrate, 
differentiate, proliferate and contribute to remodel the infarcted myocardium. 
9:15 a.m. 
869-4 Association of Left Ventricular Hypertrophy Regression 
and Heart Rate Reduction With Determinants of 
Myocardial Oxygen Consumption and Cardiovascular 
Events: The LIFE Study 
Richard B. Devereux, Kristian Wachtell, Eva Gerdts. Peter Aurup, Kurt Boman, Jonathan 
Edelman, Markku Nieminen, Vasilios Papademetriou, Ying Wan, Bjorn Dahlof. Steve 
Julius, Weill Cornell Medical Center, New York, NY 
Background: Expenmental studies have demonstrated that increased myocardral 02 
consumption demand due to left ventricular hypedrophy (LVH) increases the likekhood 
and size of myocardial infarction (Ml) with a standardized coronary occulusion, but no 
human data exist to separate the potentially beneficial effects of LVH regression and 
reduced myocardial 02 demand on the rate of Ml in treated hypertensive patients. Meth- 
ods: In a double-blind, randomized, parallel-group design 960 participants in the Losar- 
tan Intervention for Endpoint reduction in hypertension (LIFE) study (average age 66 
years, blood pressure 174198 mmHg) and ECG-documented LVH were assigned once 
daily losartan- or atenolol-based therapy and underwent echocardiography after 1.2.3,4 
and 5 years’ treatment. LV mass and the LV mass x end-systolic stress x heart rate triple 
product were measured as indices of LVH and 02 demand. Results: Blood pressure was 
reduced similarly in the two treatment arms (mean=-29.7116.2 versus -2&O/16.0 mmHg, 
NS) but heart rate fell more on atenolol (meafw7.2 versus -1.1 beats per minute, 
p<O.OOl). LV mass was reduced more in losartan than atenolol-treated patrents (mean=- 
22.0 versus -17.7 glm2, p=O.O21). In contrast, the triple product fell more on atenolol- 
based therapy (mean=-28% versus -18% p<O.OOl). In Cox regressions adjusting for 
treatment, baseline LV mass index and baseline and in-treatment pressures, each 25 g/ 
m2 lower LV mass index was associated with risk reductions (95% Cl) of 22 (5-34, 
p=O.O2)% for stroke and 33 (17-43, p=O.OOl)% for cardiovascular (CV) mortality but only 
13 (33 t0 -17, NS)% for Ml. Conclusion: Losartan-based antrhypertensive therapy 
reduced LV mass more but atenolol reduced the triple product (index of myocardial 02 
demand) by 10% more, potentially contributing to less reduction in Ml than stroke or CV 
death associated with reduction of LV mass and to less effect of losartan than atenolol on 
MI than stroke or CV death in the enhre LIFE study. 
9:30 a.m. 
869-5 The Assessment of Myocardial Viability With Delayed 
Contrast Enhancement Using Computed Tomography 
Aaron So Jennifer Hadway, Jane Sykes, Gerald Wisenberg, Frank Prato, Tin-S” Pan, -3 
Ting-Yim Lee, Lawson Health Research Institute and Robarts Research Institute, 
London, ON, Canada, General Electric Medical Systems, Waukesha, WI 
Background: Delayed enhancement of contrast has emerged as the most popular MRI 
approach to detect ischemic injury to myocardium. We have developed a CT technique 
for the quantitative measurement of myocardial distribution volume (MDV) of contrast 
media using retrospective ECG gated tine scanning. 
Methods: Four 15-25 kg beagles were used for the study. For MDV measurement, a 30 
s baseline (without contrast) tine scan was performed in synchrony with ECG recording 
using a General Electric Medical Systems (GEMS) Lightspeed multi-slice CT scanner. 
Contrast (Omnipaque, 225 mgllml) was then constantly infused for 30-60 min before the 
scan was repeated. Images were reconstructed with half-scan data (330 ms) at 0.1 S 
interval and those at end-diastole (ED) were selected with SmartScore (GEMS) and 
averaged with CT Perfusion 2 (GEMS). MDV maps were generated by subtracting the 
averaged non-contrast enhanced ED images from the corresponding averaged constant 
infusion images. The difference images were normalized to the enhancement in the 
